Multiple Myeloma
A cancer of plasma cells in the bone marrow that can affect bones, kidneys, and blood counts, with an expanding range of treatment options including CAR-T therapy.
- Plasma Cell Origin
- Bone, Kidney, and Blood Involvement
- CAR-T and Bispecific Antibody Options
- Most Common In
- Adults Over 60
- Primary Site
- Bone Marrow
- Disease Behavior
- Chronic, Relapsing-Remitting
- Advanced Therapies
- CAR-T, Bispecific Antibodies, ADCs
Condition Overview
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. In myeloma, abnormal plasma cells accumulate in the bone marrow, crowd out healthy blood cells, produce excess abnormal protein, and can damage bones and kidneys. It typically follows a chronic, relapsing-remitting course managed over many years.
Types and Subtypes
Multiple Myeloma is classified by the type of abnormal protein produced and by underlying cytogenetic features that influence prognosis and treatment.
Symptoms and Signs
Symptoms of Multiple Myeloma are often summarized by the acronym CRAB: Calcium elevation, Renal impairment, Anemia, and Bone disease, though many patients are diagnosed before all features appear.
Causes and Risk Factors
The exact cause of Multiple Myeloma is not fully understood, but several risk factors have been identified that increase the likelihood of developing the disease.
Diagnosis and Investigations
Diagnosing Multiple Myeloma involves blood and urine testing, bone marrow examination, and imaging to assess organ damage and disease extent.
Staging and Risk Groups
Multiple Myeloma is staged using the Revised International Staging System (R-ISS), which combines laboratory markers and cytogenetic risk to estimate prognosis.
Standard Treatment
Treatment for Multiple Myeloma typically combines induction therapy, stem cell transplantation for eligible patients, and long-term maintenance therapy to control the disease over time.
Advanced & Emerging Therapies
Multiple Myeloma treatment has advanced substantially with the introduction of cellular and immune-based therapies for relapsed or refractory disease.
Cellular Therapy
CAR-T Cell Therapy (BCMA-Targeted)
Engineered T cells targeting BCMA on myeloma cells, used for relapsed or refractory disease.
Immunotherapy
Bispecific Antibodies (BCMA or GPRC5D-Targeted)
Engage the patient's own immune cells to attack myeloma cells, available for relapsed disease.
Antibody-Drug Conjugate
BCMA-Targeted ADC
Delivers chemotherapy directly to myeloma cells expressing BCMA.
International Access
China-Based Cellular Therapy Centers
Patients may explore access to CAR-T and other cellular therapy programs internationally.
Biomarkers & Precision Medicine
Cytogenetic and molecular testing play a central role in risk-stratifying Multiple Myeloma and guiding treatment intensity.
When to Seek 2nd Opinion
Given the complexity and evolving treatment landscape for Multiple Myeloma, a second opinion can be valuable at multiple stages of the disease course.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes in Multiple Myeloma have improved substantially over the past two decades with the introduction of novel agents and cellular therapies. Prognosis depends on cytogenetic risk, response to initial treatment, and overall health.
Supportive Care
Supportive care addresses bone health, kidney function, infection risk, and quality of life throughout the myeloma treatment journey.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Multiple Myeloma access specialist review of pathology and cytogenetic results, connect with experienced myeloma centers, and explore CAR-T, bispecific antibody, and clinical trial options.
Get a free case reviewFrequently Asked Questions
Multiple Myeloma is a cancer of plasma cells in the bone marrow, which can lead to bone damage, kidney problems, anemia, and abnormal protein levels in the blood.
Early signs often include bone pain, fatigue, frequent infections, and abnormal blood test results, though some patients are diagnosed incidentally before symptoms appear.
Diagnosis involves blood and urine protein testing, a bone marrow biopsy, cytogenetic analysis, and imaging to assess bone involvement.
These represent a disease spectrum: MGUS is a precursor with no symptoms, smoldering myeloma has higher abnormal protein levels without organ damage, and active myeloma involves symptoms or organ damage requiring treatment.
Treatment typically includes induction combination therapy, stem cell transplantation for eligible patients, and long-term maintenance therapy to sustain remission.
CAR-T therapy uses genetically engineered T cells targeting BCMA on myeloma cells and is used for patients with relapsed or refractory disease.
Multiple Myeloma is generally considered a treatable but chronic condition; many patients achieve long periods of remission with modern therapy, though it often recurs over time.
Relapsed disease can often be treated with newer agents, including bispecific antibodies, antibody-drug conjugates, and CAR-T therapy, depending on prior treatment history.
Yes. CancerFax can help review medical reports, coordinate second opinions with myeloma specialists, and explore advanced therapy access, including CAR-T and international coordination.
Have a Multiple Myeloma Diagnosis?
Send your medical reports to CancerFax for review and explore second opinion and advanced therapy options.